Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Pharmaceutical Companies
Vical
July 28, 2014
Therapeutic focus – Herpes treatment turns to immune approach
April 30, 2014
EP Vantage Interview – Newly public UniQure looks to Glybera launch and pipeline
February 26, 2014
Therapeutic focus – Gene therapy slowly rises from the ashes
August 13, 2013
Unequivocal failure sees Vical ditch gene therapy
February 14, 2013
Ten oncology companies to avoid
July 20, 2012
Key data readouts in the second half of 2012
April 05, 2012
Vivus, Amylin and Threshold notable small cap gainers in Q1
February 16, 2012
Therapeutic focus – HIV vaccines space needs injection of enthusiasm
January 06, 2012
Small caps produce clear winners and losers in 2011
November 17, 2011
AHA 2011 - Positive data puts stem cells in spotlight
August 25, 2011
Most valuable unpartnered pipeline assets – what's hot and what's not
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 28, 2022
Access Valuable Insights Payer Behaviour Infographic
July 18, 2022
Medtech - Going steady
Editor's Picks
July 27, 2022
Aids 2022 preview – Gilead shoots for an HIV cure
July 21, 2022
Private equity gets serious about drug development
July 18, 2022
Unpacking Royalty Pharma
July 19, 2022
No plain sailing for Novartis’s PD-1 plan
July 26, 2022
Move over Aduhelm, it’s tofersen’s turn
